Omnicell Inc. <OMCL.O>: Wells Fargo cuts target price to $50 from $55
OMCL•Related News
Moleculin's Miracle R/R AML trial reports positive interim data with 37% blinded CRC in venetoclax-failed patients
MBRX•
Alnylam Pharmaceuticals Inc <ALNY.O>: Oppenheimer cuts target price to $350 from $500
ALNY•
Amundi Physical Metals issues 60,000 new Amundi Physical Gold ETC securities in tranche 888
GLD•
Netcapital says SEC stay halts Nasdaq $5 million market-value delisting rule pending review
NCPL•
Moleculin says MIRACLE trial posts 37% interim CRc rate in venetoclax-failed AML patients
MBRX•